Company Overview
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Why Investors Should Care
Generates a return on equity of 36.7%, reflecting efficient use of shareholder capital.
Revenue has grown at a 19.3% CAGR over the past five years.
Trades at a P/E of 5.0, below the sector median of 25.2.
Maintains a net profit margin of 81.2%.
Carries low leverage with a debt-to-equity ratio of 0.21.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $411.33M (+14.7% YoY); net profit $271.17M.
- Trailing 12 Months Year-on-year growth — revenue +19.3%, earnings +1059.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.3%, profit CAGR 3.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.32% |
| 1 Year: | 19.30% |
Compounded Profit Growth
| 5 Years: | 3.86% |
| 1 Year: | 1,059.22% |
Stock Price Performance
| 1 Year: | +3.49% |
| 6 Months: | -3.18% |
| 3 Months: | -5.28% |
| 1 Month: | +1.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross10d ago
- RSI (14)52.58 · Neutral
P/E of 4.95 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.7%.
- Excellent profit margin of 81.2%.
- Compounding revenue at 19.3% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INVA Innoviva, Inc. R2KR3KPHARMA | 21.33 | 4.95 | $1.54B | 0.00% | 10.33% | 36.68% | 19.32% | 3.86% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 40.49M | 58.56M | 48.64M | 69.52M | 52.38M | 67.09M | 61.68M | 79.86M | 55.18M | 64.11M | 65.75M | 75.97M | 78.68M | 78.95M | 88.69M | 85.52M | 100.81M | 97.86M | 90.06M | 108.22M | 67.26M | 76.37M | 80.99M | 67.26M | 77.50M | 99.90M | 89.51M | 88.63M | 100.28M | 107.80M | 97.99M | 119.59M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.09M | 84.99M | 73.01M | 73.31M | 83.15M | 75.54M | 75.83M | 90.62M |
| Operating Income | 745.00K | 5.11M | 8.43M | 17.29M | 17.53M | 25.88M | 27.92M | 37.66M | 29.34M | 47.83M | 40.02M | 66.41M | 40.70M | 62.67M | 57.66M | 77.22M | 52.17M | 59.76M | 60.79M | 73.64M | 76.11M | 75.79M | 84.43M | 79.48M | 96.54M | 94.55M | 77.73M | 82.55M | - | - | - | - | 25.80M | 54.69M | 43.24M | 41.43M | 48.75M | 34.58M | 38.15M | 50.85M |
| Net Income | -10.67M | - | - | - | 4.43M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted EPS | -0.09 | -0.07 | -0.04 | - | 0.04 | 0.13 | 0.13 | 0.22 | 0.15 | 0.30 | 0.21 | 0.50 | 0.27 | 0.49 | 0.43 | 2.34 | 0.31 | 0.34 | 0.36 | 0.42 | 0.59 | 0.69 | 0.26 | 0.84 | 0.90 | 0.90 | 0.20 | 0.05 | 2.80 | 0.42 | 0.02 | 0.98 | 0.46 | -0.55 | 0.02 | -0.74 | 0.77 | 1.08 | 2.22 | -1.14 |
| R&D Expense | 712.00K | 638.00K | 547.00K | - | 392.00K | 370.00K | 286.00K | - | 354.00K | 348.00K | 311.00K | - | 0 | 0 | 0 | - | - | 0 | 0 | - | 0 | 559.00K | 1.01M | 49.00K | 38.00K | 449.00K | 5.84M | 13.88M | 11.72M | 12.59M | 14.99M | 3.99M | 3.88M | 2.56M | 3.55M | 4.40M | 7.98M | 13.67M | 5.24M | 5.19M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.37M | 24.22M | 24.51M | 5.61M | 4.53M | 8.43M | 53.95M | 133.57M | 217.22M | 261.00M | 261.02M | 336.79M | 391.87M | 331.34M | 310.46M | 358.71M | 411.33M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 246.04M | 296.21M | 307.67M |
| Operating Income | -81.36M | -78.32M | -109.74M | -25.15M | -28.80M | -33.93M | 31.58M | 108.99M | 183.60M | 238.25M | 246.36M | 321.12M | 375.10M | - | 113.89M | 166.87M | 163.75M |
| Net Income | -85.30M | -83.86M | -115.34M | -18.54M | -170.70M | -168.46M | -18.76M | 59.54M | 134.14M | 395.06M | 157.29M | 224.40M | 265.85M | 213.92M | 179.72M | 23.39M | 271.17M |
| Diluted EPS | - | - | - | - | - | -1.50 | -0.16 | 0.53 | 1.17 | 3.53 | 1.43 | 2.02 | 2.87 | 2.37 | 2.20 | 0.36 | 3.30 |
| R&D Expense | 77.52M | 75.07M | 103.57M | 8.15M | 9.04M | 7.50M | 2.62M | 1.39M | 1.35M | 0 | 0 | 1.79M | 576.00K | 41.43M | 33.92M | 13.65M | 30.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 331.20M | 258.78M | 368.58M | 681.25M | 521.65M | 408.93M | 379.00M | 367.34M | 548.19M | 724.83M | 999.57M | 926.39M | 1.23B | 1.24B | 1.30B | 1.64B |
| Total Equity | -134.95M | -188.99M | -22.42M | -87.05M | 155.03M | 299.12M | -223.35M | -342.64M | -352.99M | -242.86M | 153.58M | 313.50M | 539.91M | 414.74M | 565.79M | 674.96M | 691.16M | 1.17B |
| Cash & Equivalents | 92.28M | 47.54M | 163.33M | 44.78M | 94.85M | 143.51M | 96.80M | 159.18M | 118.02M | 73.34M | 62.42M | 278.10M | 246.49M | 201.53M | 291.05M | 193.51M | 304.96M | 550.94M |
| Long Term Debt | - | - | - | - | - | 287.50M | 725.64M | 733.13M | 708.34M | 574.36M | 382.86M | 377.12M | 385.52M | 394.65M | 444.18M | 446.23M | 256.32M | 257.73M |
| Current Liabilities | - | - | 40.05M | 45.50M | 29.97M | 84.40M | 13.76M | 13.49M | 20.05M | 34.74M | 5.70M | 5.37M | 6.11M | 5.81M | 134.97M | 38.13M | 236.08M | 49.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -127.51M | -129.60M | -130.72M | 10.13M | 60.98M | 141.75M | 223.53M | 257.46M | 313.11M | 363.81M | 201.73M | 141.06M | 188.69M | 196.93M |
| Investing Cash Flow | - | - | - | -58.28M | -219.58M | -65.06M | 159.17M | -4.58M | -23.24M | 3.52M | -18.00M | -314.94M | 43.72M | -56.63M | -66.76M | -63.79M | 40.50M |
| Financing Cash Flow | - | - | - | 235.87M | 397.84M | 149.07M | -106.92M | -97.57M | -163.19M | -237.97M | -23.78M | -29.79M | -452.50M | -55.57M | -171.84M | -13.45M | 8.55M |
| Capital Expenditure | -744.00K | -861.00K | -3.63M | -2.59M | -2.73M | -689.00K | -7.00K | -278.00K | -0 | -0 | -12.00K | -13.00K | -0 | -67.00K | -411.00K | -270.00K | -1.13M |
| Free Cash Flow | - | - | - | -130.10M | -132.34M | -131.41M | 10.12M | 60.71M | 141.75M | 223.53M | 257.45M | 313.10M | 363.81M | 201.66M | 140.65M | 188.42M | 195.80M |
| Share Buybacks | - | - | - | - | 0 | 0 | 25.64M | 78.09M | 97.50M | 0 | 0 | 0 | 394.15M | 8.50M | 75.73M | 14.78M | 4.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.2% | 82.6% | 74.8% |
| Operating Margin % | -333.8% | -323.3% | -447.7% | -448.0% | -635.4% | -402.3% | 58.5% | 81.6% | 84.5% | 91.3% | 94.4% | 95.3% | 95.7% | - | 36.7% | 46.5% | 39.8% |
| Net Margin % | -350.0% | -346.2% | -470.6% | -330.3% | -3,766.6% | -1,997.7% | -34.8% | 44.6% | 61.8% | 151.4% | 60.3% | 66.6% | 67.8% | 64.6% | 57.9% | 6.5% | 65.9% |
| ROE % | 45.1% | 374.0% | 132.5% | -12.0% | -57.1% | 75.4% | 5.5% | -16.9% | -55.2% | 257.2% | 50.2% | 41.6% | 64.1% | 37.8% | 26.6% | 3.4% | 23.1% |
| ROCE % | - | -26.9% | -51.5% | -7.4% | -4.8% | -6.7% | 8.0% | 30.4% | 55.2% | 43.9% | 34.2% | 32.3% | 40.7% | - | 9.4% | 15.7% | 10.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.99% | 11.56M | $242.31M |
| 2 | Dimensional Fund Advisors LP | 6.22% | 4.49M | $94.24M |
| 3 | Vanguard Portfolio Management LLC | 5.84% | 4.22M | $88.50M |
| 4 | Renaissance Technologies, LLC | 5.59% | 4.04M | $84.65M |
| 5 | State Street Corporation | 4.52% | 3.27M | $68.53M |
| 6 | Vanguard Capital Management LLC | 4.37% | 3.16M | $66.22M |
| 7 | Millennium Management Llc | 3.52% | 2.54M | $53.29M |
| 8 | Geode Capital Management, LLC | 2.87% | 2.07M | $43.51M |
| 9 | Systematic Financial Management, L.P. | 2.80% | 2.02M | $42.43M |
| 10 | Boston Partners | 2.67% | 1.93M | $40.43M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INVA
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQVEFhUzhGbGJJNjAzSUJQTktxOXdvVjNvNS15b0JUWnRjb0RYX210b2Q0MkVUZ0pOeG5CWHhGUTJrWEZ5NWxDcG8zQXE4TTJtcWlSMnVJVmNnMm1IQ2dvU1hmaklud0g3ZllYdW1YUlV4bTU4VzlsWHViUi1SRTlBMmZ3ZnBfSHpaZDhEaV…
Innoviva (NASDAQ: INVA) CEO sees 1,130 shares withheld for taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcWRhWGkxZVhVdXl1RGV0N01sUW9QaXVUR0IxYWJHc1g4UlBzV18yWkFadFZoNlVodFJyQl9zbXhsNWZ6bllVMFpLck5kdnJpcWdOSWxwNWhBWTNZZDJCVmd0N3NvMVZEWHJoUll0VTluM0NtNDJuaFMzQl9hdTB0dEU1QzVxRG9rTGFjdn…
INVA - Innoviva Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBoTUFrVkZiZXJBU0hRYXNJMjFDVWNIZk9ETzBfcnhYQWh6SGxNSVFfYTU0ZHhTNjF3YTFCdUVoTDJ1NDlYckE?oc=5" target="_blank">INVA - Innoviva Inc Stock Price and Quote</a> <font color="#6…
(INVA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQR2ZjelU4TlVqaGVpUEtqc1pfUDRkb2dpR2ItV19FUGZWRU1JbTlxRWFxWWVXcVZKcjdDZzVMV0NINlJKV3VIVTk4ZUZUbTlCTDUtOEtiTWpMV3BaVUw3d3Qta2VXY2E1Y3lwUVphN3lWXzBVNEQzRkx1V1J2LUtfSnladXlwRkc1aV9mUE…
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic (NASDAQ:INVA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNdHBZUkI0T0NYNXcxbnFEV0Z1WFNJTzZLWFNiRDVjZEc4VXZFWFVJb214NGZpQzFsUFNkU3RlQ2Z2WVFYTmZDQ3VQdzdYWXlTTFR0UGZWWVFxSTVJdVZOVk8tV3NoUEVpdzZwSk1HYWJUMkZOM08wQlhsQnZVakNFdmp3R05BN2pBQUZVRk…
Innoviva (INVA) Faces A Valuation Test, Is The Discount Too Wide? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQNjF3WGdheXFqdGFEOV9mNGhxMzNYdkhuNmhvOEZTTXNCU21leGl3VlFFNVI0blp6eTJLNjBuRjFQaEZzb1VxalFpdTJPMlZfaWcwd3R5YUo4aVRHUk8zYmlCTzF3Ym1mS1V6WVdYbmEzYjh3aHR6bDRScmhiZl91bzBseTBkc1djQWtLcE…
INVA — Frequently Asked Questions
What is the current share price of Innoviva, Inc. (INVA)?
As of 2026-09-07 16:24 PDT, Innoviva, Inc. (INVA) trades at $21.33 on NasdaqGS. Its 52-week range is $16.67 to $24.24.
What is the market capitalisation of INVA?
Innoviva, Inc. (INVA) has a market capitalisation of $1.54B on NasdaqGS.
What is the P/E ratio of INVA?
INVA trades at a trailing price-to-earnings (P/E) ratio of 4.95. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.31.
What is the return on equity (ROE) of INVA?
INVA has a return on equity (ROE) of 36.68%. Its return on capital employed (ROCE) is 10.33%.
Is INVA a good stock to buy?
This page provides a data-driven analysis of Innoviva, Inc. (INVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.